Blood Compatibility Testing of Medical Devices: Standards, Samples, Methods, and Regulatory Requirem

Blood compatibility testing is an essential biological safety evaluation for any medical device that contacts circulating blood, covering hemolysis, thrombosis, coagulation, platelet function, and complement activation. Guided primarily by ISO 10993-4 and its Chinese counterpart GB/T 16886.4, these tests demonstrate that blood-contacting devices such as catheters, stents, dialyzers, and oxygenators do not trigger adverse blood-device interactions. This article explains the testing framework, sample types, test items, methods, and frequently asked questions to support regulatory submissions and design validation.

Technical Overview

Blood compatibility (hemocompatibility) testing evaluates the interaction between a medical device and blood to ensure the device does not cause harmful biological responses when used as intended. When foreign materials contact blood, several adverse events can occur, including thrombus formation, activation of the coagulation cascade, platelet adhesion and activation, hemolysis (destruction of red blood cells), leukocyte activation, and activation of the complement system. These responses may lead to serious clinical consequences such as embolism, inflammation, immune reactions, or organ damage.

The primary standard governing this evaluation is ISO 10993-4, "Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood," which is adopted in China as GB/T 16886.4 with identical technical content. Supporting standards include ASTM F756 for hemolysis testing of materials, ASTM F1830 for the selection of blood for in vitro evaluation, ASTM F1984 and ASTM F2065 for complement activation, and ISO 10993-12 for sample preparation. According to ISO 10993-4, testing is planned based on the intended blood contact category of the device, the contact duration, and the anticipated flow conditions, and devices are typically classified as external communicating devices with indirect blood contact (such as cannulas, infusion sets, and blood bags) or with direct circulating blood contact (such as dialyzers, oxygenators, vascular grafts, and stents).

The standard defines five categories of blood-device interaction tests: thrombosis, coagulation, platelets, hematology, and the complement system. A rational test strategy selects at least one relevant test from the applicable categories, and the evaluation may be performed using in vitro methods, ex vivo dynamic models, or in vivo animal studies depending on the risk profile of the device.

Testing Samples

Blood Collection, Storage, and Administration Devices

These devices contact blood outside the body for short durations and include blood collection tubes, blood bags and transfusion sets, syringes, needles, venous and arterial cannulae, infusion sets, and in-line blood filters. Typical evaluations focus on hemolysis and complement activation, with coagulation testing where clinically relevant.

Vascular Access and Indwelling Devices

This group includes peripheral and central venous catheters, peripherally inserted central catheters (PICC), hemodialysis catheters, pulmonary artery catheters, guidewires, balloon catheters, and introducer sheaths. Because these devices contact circulating blood directly and often remain in place for extended periods, testing usually covers hemolysis, coagulation, platelet activation, and thrombogenicity.

Extracorporeal Circulation and Blood-Processing Devices

Hemodialyzers, hemofilters, extracorporeal membrane oxygenation (ECMO) circuits, cardiopulmonary bypass oxygenators and reservoirs, apheresis and cell-separation systems, and artificial heart-lung machines represent the highest-risk category due to the large material surface area and dynamic flow conditions. These devices require comprehensive testing across all five interaction categories, particularly complement activation, which is clinically significant in procedures such as dialysis.

Long-Term and Implantable Cardiovascular Devices

Vascular grafts, coronary and peripheral stents, heart valve prostheses, septal occluders, vena cava filters, ventricular assist devices, and total artificial hearts are exposed to blood continuously at high shear stress. Thrombogenicity assessment, either through in vivo implantation studies or dynamic ex vivo flow models, is a core requirement in addition to hemolysis and coagulation testing.

Testing Items

A compliant hemocompatibility evaluation selects tests from the following interaction categories defined by ISO 10993-4:

• Thrombosis: in vivo assessment of thrombus formation, including percent occlusion, thrombus mass, thrombus score, and gross and microscopic examination of the device after exposure or implantation.
• Coagulation: prothrombin time (PT), activated partial thromboplastin time (APTT/PTT), thrombin time (TT), fibrinogen concentration, thrombin generation, and FPA (fibrinopeptide A) to evaluate effects on the plasma coagulation cascade.
• Platelets: platelet count, platelet adhesion on the material surface, platelet aggregation, mean platelet volume, and activation markers such as beta-thromboglobulin (β-TG), platelet factor 4 (PF4), and P-selectin (CD62P) expression.
• Hematology: red blood cell count, hemoglobin concentration, hematocrit, leukocyte count with differential, and leukocyte activation markers to assess cellular damage or inflammatory response.
• Hemolysis: plasma free hemoglobin concentration and calculation of the hemolytic index, which quantifies the extent of red blood cell destruction.
• Complement system: complement activation products C3a, C5a, SC5b-9, Bb, and iC3b, as well as total complement activity (CH50), to evaluate the potential for inflammatory and hypersensitivity-type reactions.

Testing Methods

Hemolysis Testing

Hemolysis is the most fundamental screening test and is performed according to ASTM F756 and ISO 10993-4 using two approaches: the direct contact method, in which whole blood is incubated with the intact device or material, and the extraction (indirect) method, in which blood is exposed to an extract prepared according to ISO 10993-12. After incubation, plasma free hemoglobin is measured spectrophotometrically, and the hemolytic index is calculated against negative (such as polyethylene or glass control) and positive controls (such as distilled water or Triton solution). A hemolytic index below 5% is generally considered acceptable, although many manufacturers adopt stricter internal limits of 2% or lower for high-risk devices.

Thrombogenicity Assessment

Thrombogenicity can be evaluated through three complementary approaches. In vivo studies involve implanting or deploying the device in an animal model under realistic flow conditions, followed by assessment of occlusion and thrombus burden. Ex vivo dynamic models, such as arteriovenous shunt loops in animals, circulate blood through the test device while measuring pressure drop, flow reduction, and thrombus mass. In vitro recirculation or flow-loop systems using human or animal blood under controlled shear conditions allow repeatable comparative screening of materials and surface coatings. The choice of model depends on the device's intended use, geometry, and contact duration.

Coagulation and Platelet Testing

Coagulation assays compare PT, APTT, TT, and fibrinogen levels between blood exposed to the test device and control blood incubated under identical conditions. Platelet studies quantify the reduction in platelet count after exposure, measure adhesion density through microscopy or protein assays, and quantify activation markers such as PF4 and P-selectin by immunoassay or flow cytometry. Careful control of anticoagulant type (heparin or citrate), blood source, holding time, and incubation temperature is critical because these parameters strongly influence results.

Complement Activation Testing

Complement activation is particularly relevant for devices with large blood-contacting surfaces, such as dialyzers and oxygenators. Human plasma or whole blood is circulated through or incubated with the device, and activation fragments C3a, C5a, and SC5b-9 are quantified by ELISA at defined time points. Results are compared with established reference materials and control circuits to determine whether the device induces unacceptable complement activation, following the principles of ASTM F1984 and related practices.

Sample Preparation and Blood Handling

Test samples are prepared according to ISO 10993-12, considering the surface-area-to-extract-volume ratio, sterilization condition, and whether the device is tested as a whole component or as representative material coupons. Blood is typically obtained from healthy human donors or selected animal species, with donor-to-donor variability addressed through adequate sample sizes and matched controls. Testing should be completed within a defined period after blood draw, and anticoagulation conditions must reflect the intended clinical use of the device.

Applications

Blood compatibility testing supports multiple stages of the medical device lifecycle and regulatory pathways:

• Regulatory submissions to authorities such as NMPA, FDA, and EU notified bodies under the EU MDR, where ISO 10993-4 evaluation is a mandatory component of the biological safety file for blood-contacting devices.
• Research and development screening of candidate materials, surface modifications, antithrombotic coatings, and hydrophilic lubricants to optimize hemocompatibility at the design stage.
• Equivalence evaluation when materials, suppliers, manufacturing processes, or sterilization methods change, demonstrating that the device's blood interaction profile remains acceptable.
• Quality control and batch release testing, most commonly hemolysis testing, for products where biological safety characteristics must be periodically verified.
• Support for clinical investigation applications, where documented hemocompatibility data underpins the safety justification for first-in-human use.

FAQ

Which devices require blood compatibility testing?

Any device that directly or indirectly contacts circulating blood requires evaluation under ISO 10993-4, including catheters, infusion and transfusion sets, blood bags, dialyzers, oxygenators, ECMO circuits, stents, grafts, heart valves, and ventricular assist devices. The specific test selection depends on the contact category, contact duration, and flow conditions defined in the device's intended use.

Which standard should blood compatibility testing follow?

The governing standard is ISO 10993-4, adopted in China as GB/T 16886.4. Supporting methods include ASTM F756 for hemolysis, ISO 10993-12 for sample preparation, and complementary ASTM practices for complement activation and in vitro blood selection. An accredited third-party laboratory can confirm the applicable standard versions for the target market.

Is a hemolysis test alone sufficient for compliance?

No. Hemolysis addresses only one of the five interaction categories. ISO 10993-4 requires selection of tests spanning the relevant categories—thrombosis, coagulation, platelets, hematology, and complement system—based on the device's blood contact type and duration. For example, a central venous catheter typically requires hemolysis plus coagulation and platelet testing, while a hemodialyzer additionally requires complement activation assessment.

What is the acceptance criterion for hemolysis?

A hemolytic index of less than 5% is the widely accepted threshold indicating non-hemolytic behavior, consistent with ASTM F756 and GB/T 16886.4 guidance. Many manufacturers and reviewers apply a stricter internal limit of 2% or lower, particularly for long-term implants and pediatric applications.

Can blood compatibility testing be performed in vitro only?

In vitro testing is acceptable for many devices with indirect or short-term blood contact, such as needles, infusion sets, and blood bags. However, devices with direct circulating blood contact and significant thrombosis risk—such as vascular grafts, stents, and oxygenators—generally require ex vivo dynamic or in vivo thrombogenicity studies to adequately characterize performance under physiological flow conditions.

How is sample preparation handled for devices with multiple materials?

Per ISO 10993-12, devices should be tested in their final finished form, including sterilization, whenever feasible. For large or complex devices, representative material coupons or the complete fluid path may be evaluated, with extraction ratios chosen to simulate worst-case clinical exposure. A documented rationale for the test sample configuration should be included in the evaluation report.